A Prospective Study of Comparison of Misoprostol and Dinoprostone for Cervical Ripening and Labor Induction.
- Author:
Hyun Haing LEE
;
Won Sik PARK
;
Seung Joo SHIN
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Misoprostol;
Cervical ripening;
Labor induction
- MeSH:
Cervical Ripening*;
Cost-Benefit Analysis;
Diagnosis-Related Groups;
Dinoprostone*;
Female;
Fetal Distress;
Humans;
Membranes;
Misoprostol*;
Oxytocin;
Pregnancy;
Prevalence;
Prospective Studies*;
Rupture, Spontaneous;
Tablets
- From:Korean Journal of Obstetrics and Gynecology
1999;42(11):2480-2485
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To compare the safety and efficacy of intravaginal misoprostol versus intracervical dinoprostone (prostaglandin E2 gel) for cervical ripening and labor induction. METHODS: 60 patients with indication for labor induction and unfavorable cervices were randomly assigned to receive either intravaginal misoprostol or intracervical dinoprostone. 50 microgram tablets of misoprostol were placed in the posterior vaginal fornix every 4 hours for a maximum of 3 doses or dinoprostone 0.5mg was placed into the endocervix every 6 hours for a maximum of 2doses. No more medication was given after either spontaneous rupture of membranes or beginning of active labor. RESULTS: Among 60 patients enrolled, 30 received misoprostol and 30 received dinoprostone. The average interval from start of induction to active labor was shorter in misoprostol group (6.5+/-3.2 hours) than in the dinoprostone group (10.7+/-7.3 hours) (p<0.05). Oxytocin augmentation of labor occurred more often in the dinoprostone group (36.7%) than in the misoprostol group (10.0%) (p<0.05). There was a higher prevalence of fetal distress (23.3% versus 3.3%) and tachysystole (16.6% versus 6.6%) in the misorprostol group than in the dinoprostone group(p<0.05). CONCLUSIONS: Vaginally administered misoprostol is an effective agent for cervical ripening and induction of labor. Furthermore, the cost of misoprostol ( 360/200microgram) is much less than that of dinoprostone ( 42,000/0.5mg). Cost benefits from administration of misoprostol are evident, especially in clinics under system of diagnosis-related group (DRG) : however when given at this dosage, it is associated with a higher prevalence of fetal distress and tachysystole than dinoprostone. Further studies to compare the safety of misoprostole to that of dinoprostone and to delineate an optimal dosing regimen for misoprostol are needed.
